

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever. Neither this announcement nor any copy hereof may be taken into or distributed in the United States.

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares and the Bonds mentioned herein have not been, and will not be, registered under the Securities Act, and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Shares or the Bonds will be made in the United States.



The United Laboratories International Holdings Limited **聯邦制藥國際控股有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

COMPLETION OF THE ISSUE OF U.S.\$130,000,000 CONVERTIBLE BONDS DUE 2021

Lead Manager

CREDIT SUISSE 

The Board is pleased to announce that all the conditions precedent to the issue of the Bonds in the principal amount of U.S.\$130,000,000 under the Subscription Agreement have been satisfied and that the issue of the Bonds was completed on 5 December 2016. The Bonds are expected to be listed on the Hong Kong Stock Exchange on 6 December 2016.

Reference is made to the announcement of the Company dated 21 November 2016 (the “**Announcement**”) in relation to the proposed issue of the Bonds. Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The making of this announcement is only for the purpose of facilitating equal dissemination of information to investors in Hong Kong and not for any other purposes.

By order of the Board of
The United Laboratories International Holdings Limited
Leung Wing Hon
Company Secretary

Hong Kong, 5 December 2016

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.